Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59

Clinical and Experimental Immunology

Volumn 115, Issue 1, 1999, Pages 13-18

  Yu, J ^d   Caragine, T ^d   Chen, S ^d   Morgan, B P ^b   Frey, A B ^a   Tomlinson, Stephen ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d NONE

Author keywords

Anti tumour antibody; Breast cancer; CD59; Complement

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DNA TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD59; BREAST NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; MICE; RATS; SPECIES SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0039636689     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00751.x     Document Type: Article

References (44)

1. 1 Parker CM, ed. Membrane defenses against attack by complement and perforins. Berlin: Springer-Verlag, 1992.
2. 2 Hakulinen J, Meri S. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest 1994; 71:820-7.
3. 3 Brasoveanu LI, Altomonte M, Gloghini A et al. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer 1995; 61:548-56.
4. 4 Bjorge L, Vedeler CA, Ulvestad E, Matre R. Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol 1994; 24:1597-603.
5. 5 Yamakawa M, Yamada K, Tsuge T et al. Protection of thyroid cancer cells by complement-regulatory factors. Cancer 1994; 73:2808-17.
6. 6 Varsano S, Frolkis I, Ophir D. Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract. Am J Resp Crit Care Med 1995; 152:1087-93.
7. 7 Hofman P, Hsi BL, Manie S, Fenichel P, Thyss A, Rossi B. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventative mechanism of malignant tumor cells against complement attack? Breast Cancer Res Treat 1994; 32:213-9.
8. 8 Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human carcinomas variably express the complement-inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay accelerating factor), and CD59 (protectin). Am J Pathol 1996; 149:129-42.
9. 9 Seya T, Hara T, Matsumoto M, Sugita Y, Akedo H. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein. J Exp Med 1990; 172:1673-80.
10. 10 Cheung N-KV, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME. Decay-accelerating factor protects human tumor cells from complement mediated cytotoxicity in vitro. J Clin Invest 1988; 81:1122-8.
11. 11 Baranyi L, Baranji K, Takizawa H, Okada N, Okada H. Cell surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma. Immunol 1994; 82:522-8.
12. 12 Rollins SA, Zhao JI, Ninomiya H, Sims PJ. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 1991; 146:2345-51.
13. 13 Tomlinson S, Wang Y, Ueda E, Esser AF. The expression and characterization of chimeric human/equine complement protein C9: localization of homologous restriction site. J Immunol 1995; 155:436-44.
14. 14 Huesler T, Lockert DH, Kaufman KM, Sodetz JM, Sims PJ. Chimeras of human complement C9 reveal the site of complement regulatory protein CD59. J Biol Chem 1995; 270:3483-6.
15. 15 Seya T, Okada M, Hazeki K, Nagasawa S. Regulatory system of guinea-pig complement C3b: two factor 1-cofactor proteins on guinea-pig peritoneal granulocytes. Biochem Biophys Res Commun 1990; 170:514-2.
16. 16 Kim YU, Kinoshita T, Molina H et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med 1995; 181:151-9.
17. 17 Ish C, Ong GL, Desai N, Mattes MJ. The specificity of alternative complement pathway-mediated lysis of erythrocytes: a survey of complement and target cells from 25 species. Scand J Immunol 1993; 38:113-22.
18. 18 Yu J, Dong S, Rushmere NK, Morgan BP, Abagyan R, Tomlinson S. Mapping the regions of the complement inhibitor CD59 responsible for its species selectivity. Biochem 1997; 36:9423-8.
19. 19 Rushmere NK, Harrison RA, van der Berg CW, Morgan BP. Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site. Biochem J 1994; 304:595-601.
20. 20 Powell MB, Marchbank KJ, Rushmere NK, Van den Berg CW, Morgan BP. Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J Immunol 1997; 158:1692-702.
21. 21 Charreau B, Cassard A, Tesson L et al. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor. Transpl 1994; 58:1222-9.
22. 22 Harlow E, Lane D. Antibodies. A laboratory manual. New York: Cold Spring Harbor Laboratory, 1988.
23. 23 Hughes TR, Piddlesden SJ, Williams JD, Harrison RA, Morgan BP. Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem J 1992; 284:169-76.
24. 24 Kinoshita T, Medof ME, Silber R, Nussenzweig V. Distribution of decay-accelerating factor in peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1985; 162:75-92.
25. 25 Seya T, Hara T, Matsumoto M, Akedo H. Quantitative analysis of membrane cofactor protein (MCP) of complement. J Immunol 1990; 145:238-45.
26. 26 Davies A, Simmons DL, Hale G et al. CD59, an Ly-6 protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex of homologous cells. J Exp Med 1989; 170:637-54.
27. 27 Yu J, Abagyan RA, Dong S, Gilbert A, Nussenzweig V, Tomlinson S. Mapping the active site of CD59. J Exp Med 1997; 185:745-53.
28. 28 Helfand SC, Hank JA, Can J, Sondel PM. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies. Cell Immunol 1996; 167:99-107.
29. 29 Rushmere NK, Tomlinson S, Morgan BP. Expression of rat CD59: functional analysis confirms lack of species specificity and reveals that glycosylation is not required for function. Immunol 1997; 90:640-6.
30. 30 Xing PX, Tjandra JJ, Stacker SA, Teh JG, McLaughlin PJ, McKenzie IFC. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol Cell Biol 1989; 67:183-95.
31. 31 Walsh LA, Tone M, Waldmann H. Transfection of human CD59 complementary cDNA into rat cells confers resistance to human complement. Eur J Immunol 1991; 21:847-50.
32. 32 Zhao J, Rollins SA, Maher SE, Bothwell ALM, Sims PJ. Amplified gene expression in CD59-transfected chinese hamster ovary cells confers protection against the membrane attack complex of human complement. J Biol Chem 1991; 266:13418-22.
33. 33 Deckert M, Kubar J, Zoccola D et al. CD59 molecule: a second ligand for CD2 in T cell adhesion. Eur J Immunol 1992; 22:2943-7.
34. 34 Menu E, Tsai BC, Bothwell ALM, Sims PJ, Bierer BE. CD59 costimulation of T cell activation. J Immunol 1994; 153:2444-56.
35. 2+-signalling. J Cell Biol 1995; 131:669-77.
36. 36 Nangaku M, Meek RL, Pippin J et al. Transfected CD59 protects mesangial cells from injury induced by antibody and complement. Kidney Int 1996; 50:257-166.
37. 37 Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989; 264:1-14.
38. 38 Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264:7768-71.
39. 39 Foreman KE, Vaporciyan AA, Bonish BK et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994; 94:1147-55.
40. 40 Canevari S, Pupa SM, Menard S. 1975-95 revised anti-cancer serological response: biological significance and clinical implications. Ann Oncol 1996; 7:227-32.
41. 41 Holliger P, Winter G. Engineering bispecific antibodies. Curr Opin Biotech 1993; 4:446-9.
42. 42 Fanger MW, Morganelli PM, Guyre PM. Bispecific antibodies. Crit Rev Immunol 1992; 12:101-24.
43. 43 Junnikkala S, Hakulinen J, Meri S. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melonoma cells. Eur J Immunol 1994; 24:611-5.
44. 44 Harris CL, Kan KS, Stevenson GT, Morgan BP. Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Clin Exp Immunol 1997; 107:364-71.